C4X Discovery Holdings PLC - Manchester, England-based drug discovery company - Shareholders pass all resolutions at general meeting, including resolution one: to cancel the admission of shares to trading on AIM in London, effective from the opening bell on Friday next week. Resolution one passes with 93% voting in favour and 6.9% voting against. Resolution two passes by a similar margin, meaning shareholders approve of C4X re-registering as a private limited company with the name C4X Discovery Holdings Ltd. This is expected to take place in the week beginning April 29.
In late March, C4X Discovery said it planned to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation. It also released its for the six months to January 31 at this time. The company swung to a GBP17.8 million pretax profit, following its GBP5.2 million loss in the first half of financial 2023. Revenue, meanwhile, soared to GBP24.6 million from GBP1.7 million.
Current stock price: 8.41 pence, down 6.6%
12-month change: down 43%
By Greg Rosenvinge, Alliance News senior reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.